The purpose of this study is to compare the good and bad effects of guselkumab to the good and bad effects of placebo. 

This Phase 3 study aims to evaluate the efficacy and safety of guselkumab in the treatment of adult participants with active fistulizing, perianal Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or biologic therapy or have medical contraindications to such therapies. 

Study is divided into screening, treatment period and follow up phase. There are 3 treatment groups in this study. Participants will have 80% chance of being put in a guselkumab group, with a 40% chance of being put in guselkumab group 1 and 40% chance of being put in guselkumab group 2 and 20% chance of being put into the placebo group (group 3). Participants will receive one IV infusion of either guselkumab (group 1 and 2) or placebo (group 3).